Eyenuk Inc. is significantly extending the scope of its artificial intelligence system for the automatic analysis of retinal images, adding the diagnosis of age-related macular degeneration (AMD) and glaucoma to the EU approved uses of Eyeart AI.
New understanding of how prostate cancer adapts to the stress of androgen receptor targeted drugs and becomes castrate-resistant, points to a lesser-studied family of lipid kinases as playing a pivotal role in this process. The findings indicate that specific inhibition of one isoform of these phosphatidylinositol-5-phosphate-4-kinases (PI5P4K) could provide a route to prevent cancer cells altering their metabolism and becoming resistant to androgen deprivation.
It is a “landmark moment” in the long-awaited upgrade of the management of clinical research in Europe, but the industry has given a lukewarm welcome to a mandate to submit all clinical trial applications via the EMA’s clinical trials information system, as of Jan. 31.
Amber Therapeutics Ltd. reported that three patients have been fitted with its closed loop bioelectrical stimulation device, which it says is the first to modulate the pudendal nerve to directly address urinary continence (UI).
A U.K. real world nationwide study of the clinical effectiveness of hybrid close loop (HCL) insulin administration systems has found they improve glycemic control in type 1 diabetes compared to the earlier generation of devices.
Perspectum Diagnostics Ltd. reported the first close at $36 million of its series C round, with the majority of the new money due to be invested in expanding U.S. uptake of its Livermultiscan diagnostic for assessing and monitoring chronic liver disease.
Neophore Ltd. announced a £6 million (US$7.4 million) extension to its series B, bringing the total for the round to £21.5 million and enabling it to take forward a second DNA mismatch repair program.
A noninvasive method for administering monoclonal antibodies reliably and reproducibly to central nervous system (CNS) targets remains a significant unmet need. Researchers in Switzerland have reported making headway in bypassing the blood-brain barrier through the intranasal delivery of full-length antibodies in rodent models. They show this delivery route leads to rapid transfer of significant amounts of a mouse antibody targeted against Nogo-A, a membrane protein that inhibits growth of neurites in the brain and spinal cord.
In what is claimed as the largest study of how digital technologies were applied to support population level research during the pandemic, scientists at the U.K. Medical Research Council’s epidemiology unit at Cambridge University have reported high, sustained levels of engagement in a fully remote COVID-19 study that ran at a time when visits to a study center were not possible.
Abbvie Inc. and Eli Lilly and Co. Inc. have pulled out of the U.K.’s voluntary pricing scheme for branded drugs in protest at the 26.5% of their revenues they would be required to pay back to the government in 2023.
